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Diltiazem hydrochloride is a calcium channel blocker generally indicated for the treatment of angina 
and hypertension, and it is extensively metabolized due to the hepatic metabolism. Formulation 
of diltiazem hydrochloride into an oro-dispersible dosage form can provide fast relief with higher 
bioavailability. The bitter taste of the drug should be masked to formulate it in a palatable form. In the 
present work, an attempt was made to mask the taste by complexation technique, with a formulation 
into an oro-dispersible dosage form, using superdisintegrants Doshion P544, crospovidone (CP) and 
sodium starch glycolate (SSG). The complexes of diltiazem hydrochloride with β-CD (1:1 molar ratio) 
were prepared by kneading, co-evaporation, co-grounding, freeze-drying and melting methods. Phase 
solubility showed stability constant 819.13M-1. Prepared inclusion complexes were evaluated for taste 
masking and characterized by I.R, XRD, DSC. Using the drug β-CD complex, oro-dispersible tablets 
were prepared and evaluated for hardness, friability, weight variation, thickness, disintegrating time 
(DT), dissolution rate and taste. Formulations with 4 % Doshion, 8 % CP and 4 % SSG showed DT of 
0.54, 0.35 and 1.23 minutes, respectively. 
Uniterms: Diltiazem hydrochloride. Cyclodextrin. Drugs/taste-masking. Freeze-drying. 
O cloridrato de diltiazem é bloqueador do canal de cálcio geralmente indicado para o tratamento de angina 
e de hipertensão e é extensamente biotransformado devido ao metabolismo hepático. A formulação do 
cloridrato de diltiazem em orodispersão pode prover rápida liberação com maior biodisponibilidade. 
O sabor amargo do fármaco deve ser mascarado para ser formulado em forma palatável. No presente 
trabalho tentou-se mascarar o sabor pela técnica de complexação, com uma orodispersão, usando 
superdesintegrantes, como Doshio P544, crospivodina (CP) e glicolato de amido sódico (SSG). Os 
complexos de cloridrato de diltiazem com β-CD (razão molar 1:1) foram preparados por mistura, 
coevaporação, comoagem, liofilização e métodos de fusão. A solubilidade de fase mostrou estabilidade 
constante de 819,13 M-1. Os complexos de inclusão preparados foram avaliados com relação ao 
mascaramento do sabor e caracterizados por IV, Difração de Raios X e DSC. Empregando-se o fármaco 
complexado com β-CD, prepararam-se comprimidos dispersíveis e avaliaram-se os mesmos quanto à 
dureza, friabilidade, variação de peso, espessura, tempo de desintegração (DT), taxa de dissolução e 
sabor. Formulações com 4% de Doshion, 8% de CP e 4% de SSG mostraram DT de 0,54, 0,35 e 1,23 
minutos, respectivamente. 
Unitermos: Cloridrato de diltiazem. Ciclodextrina. Fármacos/mascaramento de sabor. Liofilização. 
INTRODUCTION
The development of drug delivery technology to any 
molecule is based on market needs, product differentiation 
and patient compliance. In the present scenario, there is an 
ever-increasing demand for more patient-compliant dos-
age forms. One important innovation in this direction is the 
development of fast dissolving/disintegrating dosage forms. 
These have been proved ideal for the geriatric and pediatric 
populations, bedridden or traveling patients, people suffering 
from dysphasia, clinical conditions in which water intake 
is limited, and situations in which water is not available. 
S. C. Jagdale, V. U. Gawali, B. S. Kuchekar, A. R. Chabukswar908
Rapidly disintegrating/dissolving dosage forms are further 
categorized as oro-dispersible tablets and dispersible tablets. 
Oro-dispersible tablets are uncoated tablets intended to be 
placed in the mouth, where they rapidly disperse before swal-
lowing. There are many methods for formulation of rapidly 
disintegrating/dissolving dosage forms. Practically reviewing 
these methods with respect to the ease of preparation and 
cost-effectiveness, the direct compression method was found 
to be the best option. Probably one of the least recognized 
advantages of direct compression is the optimization of tablet 
disintegration, in which each primary drug particle is liberated 
from the tablet mass and available for dissolution. (Dandagi 
et al., 2006; Fini et al., 2008; Hisakadzu et al., 2002) 
Cyclodextrins (CD) are cyclic oligosaccharides 
with a hydrophilic outer surface and a lipophilic cen-
tral cavity. On account of their relatively hydrophobic 
interiors, CDs have the ability to form inclusion com-
plexes with a wide range of substrates (Loftson et al., 
1996). This complex-forming ability of CD have been 
widely exploited in the pharmaceutical field for various 
applications, including taste-masking of bitter drugs 
(Giancarlo et al., 2006; Sohi et al., 2004; Szejtli, 2004). 
The use of CD as a taste-masking agent has been 
widely reported (Noriaki et al., 2006; Patel et al., 2008; 
Rajewski et al., 1996).
Diltiazem hydrochloride is a BCS Class-I drug. It is 
very bitter and has an after taste. Diltiazem hydrochloride 
is a calcium channel blocker generally indicated for the 
treatment of angina and hypertension, and it is extensively 
metabolized, predominantly due to hepatic metabolism. 
At present, there is no ODT in the market; the drug is 
marketed as immediate sustained-release tablets, extended 
sustained-release capsules, and injections. Complexation 
with β-CD will mask the bitter taste of diltiazem HCl 
(Indian Pharmacopeia, 2007; Nappini et al., 2007). The 
formulation of ODT will show rapid onset of action and 
avoid the hepatic metabolism. 
MATERIAL AND METHODS
Material
Diltiazem hydrochloride was a generous gift from 
Themis Lab (Mumbai, India). The β-cyclodextrin (β-CD) 
was purchased from Gangwal Chemicals (Mumbai, India). 
Microcrystalline cellulose (MCC), mannitol, lactose, as-
partame, ice cream flavor, magnesium state, talc, crospo-
vidone, sodium starch glycolate, and Doshion P 544 were 
procured from SD Fine Chemicals (Mumbai, India). All 
reagents were of analytical grade. Double distilled water 
was used for all the experiments.
Methods
Complexation
Phase solubility study
Phase solubility studies were carried out at room 
temperature and in triplicate, according to the method 
reported by Higuchi and Connors (Higuchi et al., 1965; 
Loftsson et al., 2005). An excess amount of diltiazem 
hydrochloride was added to double distilled water con-
taining various concentrations of β-CD (0.002-0.1 M) in 
a series of stoppered conical flasks and then shaken for 3 
days on a rotary flask shaker. The suspensions were filtered 
through Whatman filter paper and assayed for diltiazem 
hydrochloride using a UV spectrophotometer (Varian Cary 
100, Australia) at 236 nm against blank prepared using 
same concentration of β-CD in double distilled water. The 
association constant (Ka) was calculated from the slope 
of the linear portion of the phase solubility diagram. Ac-
cording to Equation (1), Ka = Slope / Intercept (1- Slope). 
Preparation of solid complexes
The solid complexes of diltiazem hydrochloride 
with β-CD (1:1 molar ratio) were prepared (Emara et al., 
2002; Franco et al., 2008; Rawat et al., 2004) by the fol-
lowing method.
·	 Kneading method (Kn)
Diltiazem hydrochloride and β-CD were triturated 
in a mortar with a small volume of water-methanol solu-
tion. The thick slurry was kneaded for 45 minutes, then 
dried at 40 ºC. The dried mass was pulverized and sieved 
through. (#100)
·	 Co-evaporation method
The aqueous solution of β-CD was added to an al-
coholic solution of diltiazem hydrochloride. The resulting 
mixture was stirred for 1 hour and evaporated at a tempera-
ture of 45 ºC until dried. The dried mass was pulverized 
and sieved through (#100)
·	 Co-grounding
The drug was triturated with a minimum quantity of 
methanol in a glass mortar until it dissolution. Then, β-CD 
was added, and the suspension was triturated rapidly at 
room temperature until solvent was evaporated.
·	 Freeze-drying method
Physical mixtures of diltiazem hydrochloride and 
β-CD in a molar ratio of 1:1 were added to 500 mL of dou-
ble distilled water and stirred for 5 days. The suspension 
was freeze-dried (Ilshin® Freeze Dryer). The freeze-dried 
complex was pulverized and sieved through (<38 µm).
·	 Physical mixture (PM)
The physical mixtures of diltiazem hydrochloride 
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and β-CD [1:1 molar ratio] were obtained by mixing 
together the pulverized powders (#100) using a mortar 
and pestle. 
Evaluation of solid complexes
Evaluation of taste of complexes
The sample of drug-β-CD complex underwent sen-
sory evaluation by a panel of five members with respect to 
the bitter taste; the evaluation was performed by classify-
ing the bitter taste into the following five classes.
Class 5:Very strong bitter taste
Class 4:Strong bitter taste
Class 3:Moderately bitter taste
Class 2:Slightly bitter taste
Class 1:No bitter taste
The pure drug was used as a standard control, with a 
mean bitter taste of 5.0. Written consent was obtained from 
the members of the panel and it was explained that the 
procedure involved testing the taste of complexes. Each 
of the members was given the control, i.e., the pure drug. 
They were asked to compare the bitterness of each of the 
ratios of the complex with that of the control, indicating the 
level of bitterness perceived by them. The members of the 
panel were asked to gargle and wait for 20 minutes before 
another sample was given to them for tasting. The mean 
bitterness value of each of the ratios was calculated based 
upon the level of bitterness sensed by each individual 
member of the panel.
Drug content
A drug-β-CD complex equivalent to 10 mg of the 
drug was stirred with 100 mL of 0.1 N HCl for 60 minutes. 
The solution was then filtered and treated as a stock solu-
tion, containing 100 μg/mL of the drug. From this stock 
solution, the concentration of 10 μg/mL was prepared. 
Drug content was determined using the calibration curve 
of the pure drug in 0.1 N HCl spectrophotometrically at 
236 nm, using 0.1 N HCl as blank.
Infrared Spectroscopy
Infrared (IR) spectra of diltiazem hydrochloride, 
β-CD and complexes were obtained by using a Varian 640 
IR spectrophotometer (Varian, Australia) with KBr pellets. 
The scanning range used was 4000 to 400 cm-1.
X-ray Diffractometry
Diltiazem hydrochloride, β-CD, drug-β-CD com-
plexes and a physical mixture of drug-β-CD were subjected 
to powder X-Ray Diffraction (XRD). To study the XRD 
pattern, the sample was placed into an aluminum holder and 
the instrument was operated between an initial and final 2θ 
angle of 5-50°, respectively, in increments of 0.2°2θ.
Differential Scanning Calorimetry
Diltiazem hydrochloride, β-CD, and drug-β-CD 
complexes were subjected to a Differential Scanning Calo-
rimetry (DSC) study. DSC was performed on a Mettler 
DSC 30. Initially, 1.60-2.80 mg of the sample was weighed 
into an aluminum crucible and analyzed by heating at a 
scanning rate of 20 ºC/minute, over a temperature range 
of 25 to 300 ºC (Ramana et al., 2008; Mura et al., 2005)
In vitro dissolution studies
Dissolution studies of samples were performed us-
ing USP 23 type II apparatus in 900 mL of 0.01 N HCl 
and phosphate buffer with a pH of 6.8. Temperature was 
maintained at 37 ± 0.5 °C, and rotation speed was 100 rpm. 
The samples were withdrawn at time intervals of 5, 10, 15, 
20, 30, 45, 60, and 90 minutes, and analyzed spectrophoto-
metrically at 236 nm.
Formulation of tablets
The tablet consisted of a drug-β-CD freeze-dried 
complex equivalent to 30 mg of drug, mannitol, lactose, 
aspartame, ice cream flavor, magnesium stearate, talc, 
microcrystalline cellulose (PH102) and various con-
centrations (2%, 4%, 8% and 12%) of superdisintegrant 
(Doshion P 544, crospovidone, sodium starch glycolate). 
The weight of tablets in each batch was kept constant. All 
the batches were prepared by direct compression using an 
8-station rotary tablet machine Minipress-II (Rimek Ltd.).
Blending and tablet compression
Tablets containing 86.07 mg of drug-β-CD freeze-
dried complex equivalent to 30 mg of the drug were pre-
pared by direct compression method. The various formulae 
used in the study are shown in Table I. The drug, diluents, 
superdisintegrant and sweetener were passed through 
a ≠ 40 sieve. All the above ingredients were properly 
mixed together (in a polybag). Talc and magnesium stea-
rates were passed through a ≠ 80 sieve, mixed, and blended 
with the initial mixture in a polybag. The powder blend 
was compressed into tablets on an 8-station rotary tablet 
machine Minipress-II (Rimek Ltd.).
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Evaluation of rapidly disintegrating tablets
All the formulations were evaluated for charac-
teristics such as hardness, friability, weight variation, 
thickness, disintegrating time, dissolution rate and taste. 
In the weight variation test, twenty tablets were selected 
at random, and mean weight was determined using an 
electronic balance. Tablets were weighed individually and 
compared with mean weight. A Pfizer hardness tester and a 
Roche friabilator were used to test hardness and friability 
loss, respectively. Disintegration time was determined us-
ing a USP tablet disintegration test apparatus in 900 mL of 
distilled water, without disk, at room temperature. For the 
in vivo test, the tablets were given to volunteers and they 
were asked to note the disintegration time. Thickness of 
tablet was determined by using a dial caliper.
Dissolution studies
The tablets underwent a dissolution test using USP 
type II apparatus (paddle) using 900 mL of dissolution 
medium (0.1 N HCl, pH 6.8 buffer), at a speed of 100 rpm 
and at a temperature of 37.0 ± 0.5 ºC. Five-milliliter aliquots 
were withdrawn at time intervals of 0, 1, 3, 5, 10, 15, 30, 
and 60 minutes. Every time, an equal volume of fresh dis-
solution medium, which was maintained at same tempera-
ture, was added to the bulk. Samples were filtered through 
Whattman filter paper, dilutions were carried out as per 
calibration curve, and absorbance was recorded at 236 nm. 
The percentage of the labeled amount of drug released at 
each time point was calculated and a graph was plotted. 
Assay method
Twenty tablets were accurately weighed and then 
powdered. Tablet powder equivalent to 10 mg of the drug 
was stirred within 100 mL of 0.1 N HCl for 60 minutes, 
and the solution was then filtered and treated as a stock 
solution containing 100 μg/mL of the drug. From this stock 
solution, further dilutions were performed for each formu-
lation. Absorbance was measured and the concentration of 
the drug in the tablet was determined, using the calibration 
curve of pure drug in 0.1N HC1 spectrophotometrically at 
236 nm, using 0.1N HC1 as blank (Kaushik et al., 2004; 
Malke et al., 2008; Sekar et al., 2008).
Percentage Assay = Absorbance of Sample / Absor-
bance of Standard x 100
Stability testing
Temperature-dependent stability studies were car-
ried out with the optimized batches Dosh II, CP III, SSG 
II. They were packed in Alu-Alu pouches and stored under 
the following conditions for a period prescribed by the ICH 
guidelines for accelerated studies in stability chambers 
(Thermolab).
(i) 30 ± 2 o C and RH 65 % ± 5%
(ii) 40 ± 2 o C and RH 75 % ± 5%
The tablets were withdrawn after a period of 7, 14 
days, 1, 2, and 3 months, and then analyzed for visual 
defects, hardness, friability, disintegration, dissolution 
and percentage assay.
RESULTS AND DISCUSSION
The phase solubility diagram for the complex 
formation between diltiazem hydrochloride and β-CD 
is shown in Figure 1. The association constant (Ka) was 
calculated as 819.13M-1 which was within the range of 
200-5000 M-1. The phase solubility diagram shows that the 
aqueous solubility of diltiazem hydrochloride increased 
linearly with a slope of 0.933 (r2 = 0.997), as a function 
of β-CD concentration. The phase solubility diagram can 
be classified as type AL, according to Higuchi and Con-
nors. It is assumed that the increase in solubility observed 
was due to the formation of a 1:1 M inclusion complex. 
The freeze-dried complex was selected for formulation, 
because it masked the bitter taste, showed maximum drug 
content and better dissolution profile. Table I shows the 
formulae used in the preparation of the tablets containing 
the freeze-dried complex of the drug.
The bitter taste of the drug was masked after com-
plexation. The freeze-dried method resulted in the com-
plex that showed maximum masking of bitter taste of the 
drug during in vivo studies (Table II). 
The drug content percentages of the complexes are 
shown in Figure 2, and were found to be within the range 
of 94 ± 0.5 to 99 ± 0.5%.
The infrared spectra of diltiazem HCl, β-CD, 
physical mixture and CD complexes prepared by various 
methods are shown in Figure 3a, 3b, 3c, 3d, 3e, 3f , 3g 
and 3h, respectively. Drug spectrum shows prominent 
peaks at 3035 cm-1, 2966 cm-1, 2837 cm-1, and 781 cm-1, 
corresponding to aromatic C-H stretch, aliphatic C-H 
stretch, O-CH3 C-H stretch and C-H stretch (Figure 3a). 
The prominent peaks of β-CD are at 3326 cm-1, 2950 cm-1, 
1200 cm-1, and 1000 cm-1, corresponding to C-H stretch-
ing, C-H stretching-C-O asymmetric stretching, and OH 
bending, respectively (Figure 3b). The physical mixtures 
of the drug with β-CD (1:1) and of the drug with β-CD 
complexes show prominent peaks of the drug, but there 
was a reduction in peak intensity of the drug peak, which 
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TABLE I - Formulae used in the preparation of tablets
Ingredients 
(mg)
Control 
formulation
Dosh I (2 
%)
Dosh II 
(4%)
Dosh III 
(8 %)
Dosh IV 
(12%)
CP I 
(2%)
CP II 
(4%)
CP III 
(8%)
CP IV 
(12 %)
SSG I 
(2%)
SSG II 
(4%)
SSG III 
(8%)
SSG IV 
(12%)
Drug-β-CD 
complex
86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07 86.07
MCC PH 102 58.43 58.5 58.5 58.5 58.5 58.5 58.5 58.5 58.5 58.5 58.5 58.5 58.5
Lactose 50 50 50 50 50 50 50 50 50 50 50 50 50
Manitol 43.4 38.2 33 22.6 12.2 38.2 33 22.6 12.2 38.2 33 22.6 12.2
Doshion P544 - 5.2 10.4 20.8 31.2 - - - - - - - -
Crospovidone - - - - - 5.2 10.4 20.8 31.2 - - - -
Sodium starch 
glyolate
- - - - - - - - - 5.2 10.4 20.8 31.2
Aspartame 13 13 13 13 13 13 13 13 13 13 13 13 13
Magnesium 
stearate
5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2 5.2
Talc 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6 2.6
Ice cream 
flavor
1.30 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23 1.23
Total (mg) 260 260 260 260 260 260 260 260 260 260 260 260 260
TABLE II - Taste evaluation of the complexes 
Drug- 
Drug-β-CD
Mean bitterness value
Drug Drug-β-CD (1:1)
Kneading 5 3
Co-evaporation 5 3
Co-grounding 5 4
Freeze-drying 5 2
Melting method 5 4
Physical method 5 5
FIGURE 1 - Phase solubility analysis plot for diltiazem 
hydrochloride inclusion complexes.
FIGURE 2 - Drug content in drug-β-cyclodextrin (1:1) complex.
was obscured by the CD peak, indicating the formation of 
inclusion complexes. (Figure 3c, 3d, 3e, 3f, 3g, 3h).
The XRD analysis (Figure 4) was carried out to con-
firm the formation of a new solid state, i.e., the formation 
of amorphous solid state (inclusion complex formation). 
The diffractograms of the drug (4a) exhibited characteris-
tic peaks at 5.85, 9.18, 10.60, 12.54, 15.23, 19.53, 20.80, 
20.02, 25.933, and 27.331, due to the crystalline nature 
of the drug. The diffractograms of β-CD (4b) exhibited 
characteristic peaks at 10.62, 12.46, 15.42, 16.98, 20.94, 
and 22.80 due to its crystalline nature. The physical mix-
ture (4c) exhibited peaks at 10.6, 12.6, 15.4, 19.6, 23, 
25.2, and 27.4 both for the drug and for β-CD, i.e., it is 
crystalline in nature, and there is no inclusion complex 
formation. The diffractograms for the kneading method 
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(A) Drug, (B) β-Cyclodextrin, (C) Physical mixture, (D) Kneading method:(Kn), 
(E) Coevaporation method, (F) Co-grounding , (G) Freeze –Drying Method, 
(H) Melting method
FIGURE 3 - Infrared spectroscopy study.
(A) Drug, (B) β-Cyclodextrin, (C) Physical mixture, (D) Kneading method:(Kn), 
(E) Coevaporation method, (F) Co-grounding, (G) Freeze –Drying Method 
FIGURE 4 - X-ray diffraction studies.
(Kn) (4d), co-evaporation method (4e), co-grounding (4f), 
and freeze–drying method (4h) were found to be more dif-
fuse, when compared to the physical mixture, i.e., there 
is no characteristic peak which confirms the formation of 
an amorphous solid state (inclusion complex formation).
Figure 5 show the DSC thermograms of drug, β-CD 
and drug-β-CD (1:1) complexes. The DSC studies were 
carried out to confirm the interaction of the drug with 
β-CD. The DSC studies showed that endothermic peaks for 
pure diltiazem HCl and β-CD were obtained at 212 °C and 
85.11 °C, respectively. The thermogram of the drug-β-CD 
(1:1) complex showed complete disappearance of peak of 
diltiazem HCl and shift of the endothermic peak of β-CD. 
These indicate the successful inclusion complexation of 
the drug with β-CD.
From the in vitro release study (Figures 6 and 7), it 
was found that the freeze-dried complex showed improve-
ment in dissolution behavior as compared to the drug and 
other complexes. The freeze-dried complex presented 
better dissolution performance in 0.1 N HCl and pH 6.8 
phosphate buffer. This might be due to the inclusion com-
plex formation.
The prepared tablets were evaluated for weight 
variation, hardness, friability, disintegration time, and 
taste. Table III shows that the prepared formulations mask 
the bitter taste of the drug, which may be due to complex-
FIGURE 5 - Differential scanning calorimetry study.
Formulation and in vitro evaluation of taste-masked oro-dispersible dosage form of diltiazem hydrochloride 913
ation with β-CD, as well as the use of a sweetener in the 
formulation. Formulations Dosh II (4 % Doshion), CP III 
(8% CP) and SSG II (4 % SSG) show decreased DT, i.e., 
0.54, 0.35 and 1.23 minutes, respectively. Doshion con-
sists of ion exchange resins. Doshion (Table IV) showed a 
reduction in the disintegration time from 2% to 12%, but 
at 4% Doshion showed reduction in DT, when compared 
to 2%, 8% and 12%. Hence, 4% Doshion (Dosh II) was 
selected. CP (Table IV) showed a trend of decrease in DT 
as concentration increased. This was because CP shows 
a capillary mechanism of disintegration. When in contact 
with water, it replaces the air absorbed by particles. This 
weakens the intermolecular bond, breaking the tablet into 
smaller particles. As the concentration of CP increased, 
the number of capillaries also increased, thus increasing 
the channeling of water. Hence, the rate of liberation to 
primary particles increased. As compared to other super-
disintegrants, CP showed much better disintegration time 
drop and was much more effective than others. At 8%, CP 
showed decrease in DT, as compared to 2%, 4% and 12 
%. Hence, 8% CP (CP III) was selected. SSG (Table IV) 
FIGURE 6 - Drug release of the drug and its complexes in 
0.1 N HCl.
FIGURE 7 - Drug release of drug and its complexes in pH 6.8 
phosphate buffer.
TABLE III - Taste evaluation of the formulations
 
Formulation
Mean bitterness value
 Drug Formulation
Dosh I (2%) 5 2
Dosh II (4%) 5 2
Dosh III (8%) 5 2
Dosh IV (12%) 5 2
CP I (2%) 5 2
CP II (4%) 5 2
CP III (8%) 5 2
CP IV (12%) 5 2
SSG I (2%) 5 2
SSG II (4%) 5 2
SSG III (8%) 5 2
SSG IV (12%) 5 2
showed a reduction in DT at 4 % (SSG II), but at 2%, 8%, 
and 12% there was an increase in disintegration time. 
Swelling of the disintegrant particles caused expansion 
of the compact – this effect is proportional to the disin-
tegrant concentration. The rate of swelling was initially 
very fast, leveling off after a few minutes, probably due to 
confinement of the tablet and change in the viscosity of the 
penetrating liquid. This behaviour is explained by the fact 
that SSG, at higher concentrations, may act as a binder, and 
instead of swelling immediately, it binds to the particles 
surrounding it. Later on, gelling takes place. This creates 
a viscous barrier. As a result, DT increases. As compared 
to the other formulations, SSG showed higher DT.
Formulations Dosh II, CP III and SSG II showed 
maximum release in pH 6.8 phosphate buffer and 0.1N 
HCl, as compared to the other formulations (Figures 8 
and 9). 
In vivo DT for Dosh II, CP III and SSG II was almost 
the same as the in vitro time, which indicates a good in 
vitro-in vivo correlation (Table IV).
Stability data is shown in Tables V and VI. There 
was no major change in hardness, friability, disintegra-
tion, dissolution, and percentage assay for Dosh II, CP III 
and SSG II, when compared with the initial batch, which 
indicates that formulations remained stable.
CONCLUSION
Diltiazem hydrochloride, a bitter drug, could be 
successfully taste-masked using β-CD by freeze-drying 
method. The taste-masked complex was incorporated to 
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TABLE IV - Evaluation of the formulation
Parameter Control 
formulation
Dosh I 
(2%)
Dosh II 
(4%)
Dosh III 
(8 %)
Dosh IV 
(12%)
CP I 
(2%)
CP II 
(4%)
CP III 
(8%)
CP IV 
(12 %)
SSG I 
(2%)
SSG II 
(4%)
SSG III 
(8%)
SSG IV 
(12%)
Hardness (Kg/cm2)** 2.6 ± 
0.1732
2.9 ± 
1.31
3.2 ± 
1.06
3.4 ± 
0.89
3.1 ± 
0.19
2.56 ± 
0.032
2.50 ± 
0.10
2.63 ± 
0.152
2.66 ± 
0.057
2.62 ± 
0.158
2.53 ± 
0.152
3 ± 
0.100
3.1 ± 
0.100
Friability (%) 0.70 0.76 0.63 0.72 0.89 0.69 0.62 0.65 0.63 0.78 0.79 0.74 0.78
Thickness (mm)** 3.3 ± 
0.0173
3.3 ± 
0.02
3.4 ± 
0.04
3.1 ± 
0.02
3.2 ± 
0.03
3.4 ± 
0.02
3.5 ± 
0.03
3.02 ± 
0.02
3.01 ± 
0.02
3.2 ± 
0.03
3.2 ± 
0.03
3.4 ± 
0.03
3.5 ± 
0.02
DT (min)** 2.09-2.20 1.60 ± 
0.577
0.51 ± 
0.577
0.72 ± 
0.577
0.80 ± 
1.00
1.10 ± 
1.0
0.4 ± 
2.0
0.32 ± 
1.52
0.50 ± 
2.60
1.54 ± 
0.036
1.23 ± 
0.026
1.40 ± 
0.05
1.45 ± 
0.02
DT (in vivo, min)** 2.10-2.25 1.63 ± 
0.562
0.54 ± 
0.534
0.75 ± 
0.567
0.82 ± 
1.00
1.15 ± 
1.04
0.42 ± 
1.80
0.35 ± 
1.46
0.54 ± 
2.10
1.60 ± 
0.040
1.25 ± 
0.030
1.45 ± 
0.05
1.48 ± 
0.03
Mean weight (mg)* 256.77 ± 
0.56
255.70 ± 
0.6083
255.6 ± 
0.5292
255.2 ± 
1.058
256.83 ± 
0.5923
256.93 ± 
0.9018
256 ± 
1.00
256.06 ± 
0.702
254.73 ± 
0.25
257.16 ± 
1.04
256.83 ± 
0.763
255.5 ± 
0.500
255.5 ± 
1.322
* Mean ± SD, n = 20, ** Mean ± SD, n = 6
FIGURE 9 - Drug release from tablet in 0.1 N HCl.FIGURE 8 - Drug release from tablet in pH 6.8 phosphate buffer.
TABLE V - Stability Testing-i) 30 ± 1 oC and RH 65 % ± 5%
Formulation Parameter Initial 30 ºC / 65% RH 
7 days
30 ºC / 65% RH 
14 days
30 ºC / 65% RH 
1 month
 30 ºC / 65% RH 
2 months
 30 ºC / 65% RH 
3 months
Dosh II Hardness** (Kg/cm2) 3.2 ± 1.06 3.1 ± 0.19 3.2 ± 0.10 3.13 ± 0.057 3.3 ± 0.34 3.2 ± 0.15
Friability (%) 0.63 0.63 0.69 0.71 0.72 0.69
Thickness (mm)** 3.4 ± 0.04 3.3 ± 0.02 3.2 ± 0.11 3.2 ± 0.057 3.3 ± 0.04 3.2 ± 0.02
DT (min)** 0.51 ± 0.577 0.51 ± 0.577 0.51 ± 1.00 0.53 ± 1.154 0.52 ± 1.20 0.51 ± 0.546
Assay (%) 92.87 92.38 92.48 92.50 92.45 92.58
Mean weight (mg)* 255.6 ± 0.5292 255.70 ± 0.6083 254.66 ± 0.57 254 ± 1.00 255.23 ± 0.489 255.30 ± 0.372
CP III Hardness (Kg/cm2 )** 2.63 ± 0.152 2.66 ± 0.057 2.66 ± 0.010 2.65 ± 0.0153 2.64 ± 0.149 2.61 ± 0.042
Friability (%) 0.65 0.65 0.67 0.65 0.70 0.68
Thickness (mm)** 3.02 ± 0.02 3.02 ± 0.02 3.03 ± 0.0058 3.02 ± 0.015 3.1 ± 0.02 3.05 ± 0.06
DT (min)** 0.32 ± 1.52 0.33 ± 1.52 0.34 ± 0.577 0.35 ± 1.00 0.33 ± 1.47 0.34 ± 1.53
Assay (%) 93.67 93.15 93.29 93.20 93.38 93.40
Mean weight (mg)* 256.06 ± 0.702 256.93 ± 0.9018 256.33 ± 0.577 255.66 ± 0.577 256.70 ± 0.356 255.43 ± 0.521
SSG II Hardness** (Kg/cm2 ) 2.53 ± 0.152 2.53 ± 0.152 2.56 ± 0.0346 2.55 ± 0.0153 2.60 ± 0.054 2.55 ± 0.0134
Friability (%) 0.79 0.78 0.76 0.79 0.75 0.78
Thickness (mm)** 3.2 ± 0.03 3.2 ± 0.03 3.2 ± 0.100 3.23 ± 0.057 3.1 ± 0.10 3.2 ± 0.04
DT (min)** 1.23 ± 0.026 1.23 ± 0.026 1.24 ± 0.010 1.24 ± 0.015 1.23 ± 0.025 1.25 ± 0.014
Assay (%) 91.34 91.21 90.89 91.37 91.45 91.69
* Mean ± SD, n = 20, ** Mean ± SD, n = 6
Formulation and in vitro evaluation of taste-masked oro-dispersible dosage form of diltiazem hydrochloride 915
TABLE VI - Stability Testing-i) 40 ± 2 o C and RH 75 % ± 5%
Formulation Parameter 30 ºC / 65% RH 
7 days
30 ºC / 65% RH 
14 days
30 ºC / 65% RH 
1 month
 30 ºC / 65% RH 
2 months
 30 ºC / 65% RH 
3 months
Dosh II Hardness (Kg/cm2)** 3.1 ± 0.200 3.13 ± 0.1528 3.2 ± 0.100 3.2 ± 0.150 3.1 ± 0.260
Friability (%) 0.67 0.74 0.78 0.72 0.70
Thickness (mm)** 3.2 ± 0.100 3.16 ± 0.152 3.16 ± 0.0577 3.3 ± 0.100 3.18 ± 0.0512
DT (min)** 0.52 ± 0.57 0.51 ± 1.00 0.52 ± 1.52 0.53 ± 1.00 0.51 ± 0.58
Assay (%) 92.30 92.42 92.53 93.10 92.81
Mean weight (mg)* 255.33 ± 0.57 255.66 ± 0.57 255.33 ± 0.57 255.40 ± 0.56 256.20 ± 0.58
CP III Hardness (Kg/cm2)** 2.66 ± 0.057 2.7 ± 0.100 2.73 ± 0.152 2.60 ± 0.054 2.75 ± 0.052
Friability (%) 0.68 0.73 0.79 0.70 0.75
Thickness (mm)** 3.02 ± 0.010 3.03 ± 0.010 3.016 ± 0.015 3.1 ± 0.012 3.08 ± 0.021
DT (min)** 0.33 ± 0.57 0.35 ± 1.00 0.36 ± 1.52 0.34 ± 1.00 0.35 ± 1.42
Assay (%) 93.10 93.39 93.45 93.12 92.90
Mean weight (mg)* 256.66 ± 0.57 256 ± 1.00 256 ± 0.42 256 ± 1.00 257.10 ± 0.564
SSG II Hardness** (Kg/cm2) 2.55 ± 0.020 2.56 ± 0.0153 2.56 ± 0.010 2.58 ± 0.06 2.57 ± 0.01
Friability (%) 0.68 0.76 0.81 0.75 0.70
Thickness (mm)** 3.16 ± 0.057 3.2 ± 0.10 3.1 ± 0.10 3.2 ± 0.05 3.1 ± 0.10
DT (min)** 1.22 ± 0.010 1.23 ± 0.020 1.23 ± 0.010 1.24 ± 0.021 1.23 ± 0.022
Assay (%) 91.20 91.43 91.62 91.70 91.60
Mean weight (mg)* 256.66 ± 0.577 256 ± 1.00 257 ± 1.00 256.70 258.10
* Mean ± SD, n = 20, ** Mean ± SD, n = 6
prepare oro-dispersible tablets. Tablets formulated with 
Doshion P544 (4%), crospovidone (8%), and sodium 
starch glycolate (4%) as superdisintegrant showed faster 
disintegration and drug release. The prepared formulation 
offered significant results in terms of improving taste and 
bioavailability.
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